RT Journal Article
T1 [Parenteral nutrition-associated complications in patients with SARS-CoV-2 infection].
T2 Complicaciones asociadas a la nutrición parenteral en los enfermos con infección por SARS-CoV-2.
A1 Valero Zanuy, María Ángeles
A1 Maíz Jiménez, María Irene
A1 Villa López, Gema
A1 González Barrio, Iván
A1 Gomis Muñoz, Pilar
A1 León Sanz, Miguel
K1 Hiperglucemia. Hipertrigliceridemia. Hepatopatía. Infección asociada al catéter. Nutrición parenteral.
AB Background: it is unknown whether patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19 are at greater risk of developing complications associated with parenteral nutrition (PN). Aim: to describe the incidence, risk factors, and clinical impact of complications in patients with ARDS-COVID-19 receiving PN. Methods: a prospective cohort study of 87 patients with ARDS-COVID-19 infection. The incidence of complications and odds ratios of risk factors were analysed. Results: age ≥ 65 years (OR, 2.52, 95 % CI: 1.16 to 5.46), obesity (OR, 3.34, 95 % CI: 2.35 to 4.33) and treatment with propofol (OR, 2.45, 95 % CI: 1.55 to 3.35) or lopinavir/ritonavir (OR, 4.98, 95 % CI: 3.60 to 6.29) were risk factors for hipertriglyceridemia. Obesity (OR, 3.11, 95 % CI: 1.10 to 8.75), dyslipidemia (OR, 3.22, 95 % CI: 1.23 to 8.40) or treatment with propofol (OR, 5.47, 95 % CI: 1.97 to 15.1) were risk factors for intravascular catheter-related infection. No risk factors were described for hiperglycemia. Mortality was higher in patients with intravascular catheter-related infection (46.7 % vs 10.8 %, p = 0.014). Mortality risk was higher in older patients (OR, 2.74, 95 % CI: 1.08 to 6.95) or patients with intravascular catheter-related infection (OR, 3.22, 95 % CI: 1.23 to 8.40). Conclusions: the incidence of complications associated with PN in patients with COVID-19-related ARDS is frequent. The mortality risk is higher in older patients or those with catheter-related infection.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21756
UL http://hdl.handle.net/10668/21756
LA es
DS RISalud
RD Apr 5, 2025